CBL-514: The Fat-Killing Injection in Trials Now — What It Is, What the Data Actually Shows, and Why You Can't Get It Yet
CBL-514 is an experimental injection that makes fat cells self-destruct. Phase 2 results, the new visceral-fat data, Phase 3 status, safety, and the honest bottom line for regular people trying to lose fat.
10/18/20265 min read
Every few years a headline shows up promising to melt belly fat with an injection. Most of them fade. This one — CBL-514 — is worth a serious look, because unlike the miracle creams and “fat-burning” teas, it is a real drug, from a real company, moving through real clinical trials with published data. It is also not available to you yet, no matter what some website is selling. Both things are true, and this post will walk through both.
What CBL-514 actually is
CBL-514 is an experimental injectable drug from Caliway Biopharmaceuticals, a clinical-stage company in Taiwan. It is a small-molecule drug given as injections under the skin (subcutaneous) into an area of fat — in the trials, mostly the abdomen.
It works in a completely different way from Ozempic, Wegovy, or Zepbound. Those GLP-1 drugs work mainly through your brain and gut: less hunger, less food, less weight everywhere. CBL-514 doesn’t touch your appetite at all. Injected into a fat deposit, it is designed to trigger apoptosis — programmed cell death — in the fat cells (adipocytes) right there. According to the developer’s research, it does this by inhibiting a protein called DYRK1B and switching on the cell’s own self-destruct machinery (caspase-3 and the Bax/Bcl-2 pathway).
That distinction matters, and here is the plain-English version:
Normal fat loss shrinks fat cells. The cells are still there, smaller, waiting to refill — one reason regain is so common.
CBL-514 aims to remove fat cells. Dead cells get cleared away by the body. Fewer cells in that spot means that spot has less capacity to store fat again.
It is local treatment, not whole-body weight loss. Think “spot reduction, if the trials hold up,” not “a shot that makes you thin.”
What the trials have shown so far
Phase 2 (study CBL-0202, published in the Aesthetic Surgery Journal). Eight weeks after the final treatment, over 60% of people in the CBL-514 group had lost at least 200 mL of subcutaneous fat in the treated area — compared with 0% on placebo. About 43% got at least a 150 mL reduction after just one treatment. In the per-protocol analysis, average fat volume in the treated area fell 28.1% versus placebo. For scale: a study the researchers cite found abdominal liposuction removes about 183 mL of fat on average — which is why the company positions this as a possible non-surgical alternative to liposuction for large-area abdominal fat.
Phase 2b (study CBL-0205, United States and Canada). This was the largest CBL-514 study yet — 173 people with moderate-to-severe abdominal fat, up to four treatments spaced three weeks apart. It met its primary and key secondary endpoints: 54.2% of treated participants achieved at least a 20% reduction in fat volume four weeks after treatment, and nearly 80% (per-protocol) improved at least one grade on the abdominal fat rating scale.
The visceral fat surprise. The most interesting newer data came from MRI sub-analyses of the Phase 2b studies, presented at the European Association for the Study of Diabetes (EASD) meeting. Visceral fat — the deep fat wrapped around your organs, the kind most strongly tied to type 2 diabetes and heart disease — fell by an average of about 12% four weeks after the final treatment in the CBL-514 groups, while the placebo group gained about 5.7%. The reduction was largely maintained (about 10.5% below baseline) at the 8–12 week follow-ups. Be honest about what this is, though: a sub-analysis from a trial sponsor, presented at a conference. It is promising. It is not yet the same thing as proof from a big trial designed to test visceral fat as its main question.
Safety so far. Across these studies, the pattern has been consistent: mostly mild-to-moderate injection-site reactions (the kind you’d expect from a grid of injections — redness, bruising, tenderness), and no drug-related serious adverse events reported in the Phase 2 programs. That is a favorable early profile, not a guarantee — Phase 3 exists precisely to find the rarer problems in a much larger group of people.
Where it stands right now
Phase 3 has started. Caliway’s pivotal Phase 3 trial, called SUPREME-01, received ethics-board (IRB) approval and began enrolling in 2026; a second pivotal trial has been in preparation. These large trials in large-area abdominal fat reduction are the ones an FDA application would stand on.
A GLP-1 combination trial is coming. The FDA has cleared a Phase 2 study (CBL-0201WR) combining CBL-514 with tirzepatide (Zepbound) in about 120 U.S. adults — aimed squarely at stubborn abdominal fat and the weight-regain problem people hit during and after GLP-1 treatment. The logic: the GLP-1 shrinks fat everywhere; CBL-514 removes cells in the spot that won’t budge.
It is also being tested for Dercum’s disease, a rare condition of painful fat growths, where Phase 2 results showed meaningful pain reduction.
It is approved nowhere. Not in the U.S., not in Taiwan, not anywhere. There is no legal prescription, no clinic that can legitimately offer it, and no price — anyone who tells you otherwise is ahead of the science.
The warning that matters most
Because CBL-514 is getting attention, “research chemical” and peptide-style websites already list powders and vials labeled “CBL-514” for sale. Understand what that is: an unverified substance from an unregulated seller, with no guarantee it is the same molecule Caliway is testing, at the same purity, or safe to put in a human body. The real drug is a proprietary compound whose structure hasn’t even been publicly disclosed. Whatever is in those vials, it is not the tested drug in any meaningful sense, and injecting it is gambling with exactly the risks the clinical-trial process exists to catch. I know the temptation is real — I write this blog because I’ve lived the fat fight — but this is a hard no until the real thing is approved and prescribed.
The honest bottom line for regular people
If the Phase 3 results hold up, CBL-514 could become something genuinely new: the first approved injectable for large-area localized fat reduction — a non-surgical option for the stubborn abdominal fat that survives an otherwise successful weight loss. The visceral-fat signal, if it survives bigger trials, would make it more interesting still.
But read the fine print with me:
It treats areas, not overall weight. Someone with 50 pounds to lose still needs the unglamorous work — food, movement, sleep — first.
Removing fat cells in one spot does not make you regain-proof. The fat cells you still have can still grow, and new fat can still go elsewhere. The habits still decide the long run.
There is no timeline you can bank on. Phase 3 trials take time, regulators take more, and plenty of promising Phase 2 drugs die in Phase 3. “Results expected in the coming years” is the honest version.
I’ll be watching this one, and I’ll update this post as the Phase 3 data lands. Until then: interesting science, real data, not a product. Don’t buy the vial.
This post is education, not medical advice. CBL-514 is an investigational drug; trial results above are as reported by the study sponsor and investigators and may change as larger trials complete. Talk to your own clinician about any fat-loss treatment.
Sources:
Caliway Biopharmaceuticals — Phase 2 (CBL-0202) results and Aesthetic Surgery Journal publication
pharmaphorum — EASD coverage, Phase 2 visceral fat and subcutaneous results